Amyotrophic Lateral Sclerosis
698
112
145
331
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
96 trials with published results (14%)
Research Maturity
331 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.0%
56 terminated out of 698 trials
85.5%
-1.0% vs benchmark
6%
43 trials in Phase 3/4
29%
96 of 331 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 331 completed trials
Clinical Trials (698)
Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Study of Predictive Factors of Progression of Motor Neurone Disease
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)
HEALEY ALS Platform Trial - Master Protocol
Ultra-high-caloric, Fatty Diet in ALS
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The National Amyotrophic Lateral Sclerosis Registry
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
EIM Via the Myolex mScan as an ALS Biomarker